Difference between revisions of "Nabhan C, et al. Leuk. Lymphoma (2004) cited as Ref 551 in DOI: 10.1038/s41392-020-0110-5 (Q9814)"
Jump to navigation
Jump to search
(Created claim: Published In Name String (P102): Leuk. Lymphoma, #quickstatements; #temporary_batch_1590006349955) |
(Created claim: Page(s) (P105): 2269-2273, #quickstatements; #temporary_batch_1590074839150) |
||
| (2 intermediate revisions by the same user not shown) | |||
| Property / Volume | |||
| + | 45 | ||
| Property / Volume: 45 / rank | |||
| + | Normal rank | ||
| Property / title | |||
| + | A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) (English) | ||
| Property / title: A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) (English) / rank | |||
| + | Normal rank | ||
| Property / Page(s) | |||
| + | 2269-2273 | ||
| Property / Page(s): 2269-2273 / rank | |||
| + | Normal rank | ||
Latest revision as of 15:45, 21 May 2020
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
| Language | Label | Description | Also known as |
|---|---|---|---|
| English |
Nabhan C, et al. Leuk. Lymphoma (2004) cited as Ref 551 in DOI: 10.1038/s41392-020-0110-5
|
Cited in: "Targeting cancer stem cell pathways for cancer therapy" in Signal Transduct Target Ther; 2020 ; 5 8
|
Statements
Nabhan C
0 references
2004
0 references
Leuk. Lymphoma
0 references
45
0 references
A pilot trial of rituximab and alemtuzumab combination therapy in patients with relapsed and/or refractory chronic lymphocytic leukemia (CLL) (English)
0 references
2269-2273
0 references
